Cowen and Company’s LumiraDx Limited Warrant LMDXW Stock Holding History

Cowen and Company’s Portfolio LMDXW Stock Details LMDXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,495	Closed	-$855	–	728
2022 Q4	$855	Buy	+14,495	New	+$1.98K	﹤0.01%	627
2021 Q4	–	Sell	-30,000	Closed	-$35K	–	802
2021 Q3	$35K	Buy	+30,000	New	+$34.8K	﹤0.01%	422

Other funds holding LMDXW

CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Cowen and Company's LMDXW Position: Q1 2023 in Review

Cowen and Company sold out of LumiraDx Limited Warrant (LMDXW) in Q1 2023, closing a stake of 14,495 shares — an estimated $855 sold.

Cowen and Company first reported a position in LMDXW in Q3 2021 and held it in 2 quarters. The position peaked at $35K in Q3 2021. 15 funds tracked by Wall St. Rank hold LMDXW as of Q1 2023.

Cowen and Company reported no remaining LumiraDx Limited Warrant position as of Q1 2023 after selling out during the quarter.
Cowen and Company sold 14,495 LumiraDx Limited Warrant shares in Q1 2023, an estimated $855.
Cowen and Company first reported a position in LumiraDx Limited Warrant in Q3 2021 and held it in 2 quarters.
Cowen and Company's LumiraDx Limited Warrant position peaked at $35K in Q3 2021.
15 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.